Avience Biomedicals

Avience Biomedicals SME IPO

Listed

NSE SMEOpens 18 June 2026Closes 22 June 2026

Avience Biomedicals Limited, incorporated in June 2024, is an ISO-certified healthcare and biotechnology solutions company. The enterprise specializes in manufacturing, supplying, and exporting high-precision molecular…

Show more
Live GMPSubscriptionAllotment
Price band
₹196 - ₹208
Issue size
₹30.24 Cr
Lot size
600 shares
Type
NSE SME
GMP
₹145 (+69.7%)
Est. listing
₹353
Est. profit / app
₹1,74,000
Retail quota
35.08%

Key ratios

As per RHP / filings
Face value
₹10
EPS
12.56
P/E ratio
16.56
RoNW
22.38%
ROE
22.38%
Debt / Equity
0.94
Advertisement

Timeline

  1. IPO Opens

    18 Jun 2026

  2. IPO Closes

    22 Jun 2026

  3. Allotment

    23 Jun 2026

  4. Listing

    25 Jun 2026

IPO Timeline & Listing Details

EventDate
IPO Open Date18 June 2026
IPO Close Date22 June 2026
Allotment Date23 June 2026
Listing Date25 June 2026

Investment Categories

CategoryLotsAmount
Individual
2₹2,49,600
SHNI (Min)
3₹3,74,400
SHNI (Max)
8₹9,98,400
BHNIAbove ₹10,00,000
9₹11,23,200

IPO Reservation Details

CategoryReservation
QIB (Qualified Institutional Buyer)49.83%
NII (Non-Institutional Investor)15.09%
SHNI (Small Non-Institutional Investor)4.75%
BHNI (Big Non-Institutional Investor)9.49%
Retail35.08%
Market Maker5.65%
Total100.00%

IPO Objectives

  • Part financing capital expenditure requirements towards setting up a new diagnostic and medical equipment manufacturing unit at the dedicated Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA) in Gautam Buddha Nagar, Uttar Pradesh (₹15.96 Cr).
  • Funding ongoing incremental working capital requirements of the company (₹8.25 Cr).
  • General Corporate Purposes.

Strengths

  • The company builds a Clean Product Diversity Moat, offering a comprehensive diagnostic matrix that scales seamlessly across quick-turnaround rapid test kits, advanced biochemistry analyzers, and molecular PCR assays.
  • It benefits from Strategic Medical Park Integration, as capital allocations are directed entirely into a new greenfield facility located inside the specialized YEIDA Medical Device Park zone, yielding significant macro logistics and supply chain advantages.
  • The business commands Strong Specialized Sector Margins, recording solid operational parameters with an active PAT margin of 15.86% and an EBITDA margin of 24.70% as of late 2025.
  • It maintains strong B2G Tender Runway Visibility, with a specialized focus on institutional B2B laboratories and structural, high-volume government medical procurement contracts.
  • The issue enjoys Positive Market Sentiments, capturing healthy early grey market momentum with an active premium quote tracking at ₹70, suggesting a projected entry layer near ₹278 per share.

Weaknesses

  • The firm has an Incredibly Brief Corporate Track Record, having been incorporated exceptionally recently in June 2024, which presents a very short baseline historical performance arc for long-term operational validation.
  • It faces High Concentration & Regulatory Risks, as its core revenues and operational clearances remain heavily bound to stringent drug compliance certifications, institutional purchase milestones, and government procurement timelines.
  • The business manages Substantial Balance Sheet Leverage, with total borrowings growing to ₹26.73 Cr by early 2026, leading to an elevated pre-issue debt-to-equity matrix layer tracking at 0.94.
Advertisement

Financial Performance

Period Ended31 Jan 2026 (10M)31 Mar 202531 Mar 2024
Assets (₹ Cr.)66.0756.5234.65
Revenue (₹ Cr.)41.9445.9724.37
PAT (₹ Cr.)5.747.232.14
Net Worth (₹ Cr.)28.5222.786.21

Peer Comparison

CompanyP/B RatioP/E RatioRONW (%)Net Worth (₹ Cr.)

Subscription Details

Daily Bids Status

CategoryDay 1Day 2Day 3
QIB0x0.03x196.77x
NII13.49x66.36x597.23x
S-HNI13.14x66.91x451.32x
B-HNI13.66x66.08x670.18x
RII15.69x58.97x401.21x
Total10.75x43.79x385.24x

Overall Subscription Statistics

CategoryShares OfferedShares BidBid Amount (₹ Cr)
QIB2,73,6005,38,37,4001,119.82
NII2,07,00012,36,25,8002,571.42
Small NII69,0003,11,41,200647.74
Big NII1,38,0009,24,84,6001,923.68
RII4,81,20019,30,64,4004,015.74
Total9,61,80037,05,27,6007,706.97
Advertisement

Company Details

  • Avience Biomedicals Ltd.
  • C-11, Block-C, Community Centre, Janakpuri A-3, Delhi, New Delhi, 110058
  • 1800-12-04-636
  • info@avienbio.com
  • https://avienbio.com/

Registrar Details

Frequently Asked Questions

What does Avience Biomedicals do?
Avience Biomedicals manufactures and supplies medical diagnostic products, including in-vitro diagnostic (IVD) test kits, biochemistry analyzers, and molecular diagnostic solutions for healthcare institutions and laboratories.
What are the IPO dates for Avience Biomedicals SME IPO?
The Avience Biomedicals SME IPO will open for subscription on June 18, 2026, and close on June 22, 2026.
What is the price band and minimum investment for Avience Biomedicals IPO?
The IPO price band is fixed at ₹196 to ₹208 per share. Retail investors need to apply for a minimum of 2 lots (1,200 shares), requiring an investment of ₹2,49,600 at the upper price band.
What is the Grey Market Premium (GMP) of Avience Biomedicals IPO today?
As of June 15, 2026, the Grey Market Premium (GMP) of Avience Biomedicals IPO is around ₹70 per share, indicating an estimated listing price of about ₹278.
Where will Avience Biomedicals IPO be listed?
Avience Biomedicals IPO is proposed to be listed on NSE SME (NSE Emerge), with the tentative listing date set for June 25, 2026.

Avience Biomedicals SME IPO News & Updates

Follow the latest updates for Avience Biomedicals SME IPO, including grey market moves and allotment news.

Avience Biomedicals SME IPO IPO Pages

Open related pages for this IPO: details, GMP, subscription, allotment, review, FAQ, registrar, timeline, and news.

Avience Biomedicals SME IPO Details

Issue size, price, financials, and company info

Avience Biomedicals SME IPO GMP

Live grey market premium and listing estimate

Avience Biomedicals SME IPO Subscription

QIB, NII, Retail, SHNI and BHNI subscription

Avience Biomedicals SME IPO Allotment

Allotment date, chances, and check by PAN

Avience Biomedicals SME IPO Review

SWOT, strengths, risks, and IPO review

Avience Biomedicals SME IPO FAQ

Common questions on dates, GMP, and allotment

Avience Biomedicals SME IPO Registrar

Registrar website and how to check allotment

Avience Biomedicals SME IPO Timeline

Open, close, allotment, and listing dates

Avience Biomedicals SME IPO News

Updates, blogs, and latest IPO news

Sources

We match Avience Biomedicals SME IPO IPO numbers with official sources. For final dates and allotment results, double-check the registrar or exchange.

  • SEBIRules for IPO allotment and disclosures in India
  • NSEExchange notices, bidding data, and listing updates
  • BSEExchange notices and IPO allotment check tools
  • RHP / Offer DocumentCheck the company RHP on NSE/BSE or the IPO detail page
  • Skyline Financial Services Pvt.Ltd.Official site to check allotment status for this IPO

Also read our Editorial Policy, How GMP is calculated, How allotment chances work, and IPO fund allocation.

Reviewed by

Dinesh Agrawal · Lead IPO Analyst

15+ years in Indian markets and IPO research. He reviews IPO dates and key details before they go live.

Loading comments...